Abcam, ab316323, Anti-VGLUT3 antibody [EPR28534-165] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal VGLUT3 antibody. Carrier free. Suitable for IHC-P, ICC/IF, IHC-Fr and reacts with Transfected cell line - Mouse, Mouse samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR28534-165,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse,
Applications:ICC/IF, IHC-P, IHC-FrSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab316323 is the carrirer-free version of
ab316322
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
VGLUT3 also known as Vesicular Glutamate Transporter 3 or SLC17A8 functions as a transporter responsible for loading the neurotransmitter glutamate into synaptic vesicles in neurons. It has a molecular mass of approximately 65 kDa. VGLUT3 expression occurs in specific regions of the central nervous system such as the hippocampus and striatum as well as in sensory regions like the cochlea. This transporter lacks the abundance compared to other VGLUTs making its presence more strategically targeted in its roles.
Biological function summary
VGLUT3 modulates neurotransmitter signaling by facilitating glutamate release in both excitatory and modulatory circuits. It operates not strictly as part of a homomeric complex but interacts closely with other synaptic proteins to regulate neurotransmission. VGLUT3 presence in serotonin and dopamine neurons indicates its role in modulating their transmission suggesting a diverse function beyond typical excitatory neurotransmitter release. This transporter's activity influences synaptic plasticity and firing patterns vital for maintaining neural circuit balance.
Pathways
VGLUT3 integrates into the glutamatergic transmission pathway and the modulation of dopaminergic and serotonergic pathways. It works alongside VGLUT1 and VGLUT2 though each has a different regional brain expression allowing diverse neurotransmitter interactions in neural signaling. The transporter interacts with synaptic machinery influencing pathways responsible for synaptic vesicle recycling and neurotransmitter homeostasis ensuring effective transmission functions in responsive neurons.
VGLUT3 influences conditions such as epilepsy and schizophrenia. Its dysfunction can lead to improper glutamate levels in the synaptic cleft disrupting neural excitability and causing conditions like seizures or altered neuropsychiatric states. VGLUT3 shares connections with transport proteins like SLC1A1 affecting glutamate transport across membranes. Understanding these associations aids in therapeutic target development where modulating VGLUT3 function could address glutamatergic dysregulation contributing to these disorders.